Neuroendocrine system as therapeutic target of vitex agnus castus fruit extract for premenstrual syndrome


  • А. Г. Резников MD, professor, academician of the NAM S of Ukraine, corresponding member of NAS of Ukraine, chief of the Endocrinology of Reproduction and Adaptation Department, Ukraine



premenstrual syndrome, neuroendocrine system, prolactin, Agnus Castus, Cyclodynon, Mastodynon


The article regards to neuroendocrine mechanisms of development of latent hyperprolactinemia in the patients with premenstrual syndrome (PMS) and to some aspects of its impact on water-salt metabolism and ovarian cyclicity. The author has proposed the concept of interrelation between neurotransmitters and regulatory peptides in neuroendocrine control of prolactin secretion in PMS patients with a special reference to the role of hypothalamic tubero-infundibular dopaminergic system and galanin. According to this concept, hypothalamic dopamine is communicative link between stress- and estrogen-induced prolactin secretions. Given the current knowledge on the PMS pathogenesis, usage of Cyclodynon and Mastodynon which contain a special Vitex Agnus Castus fruit extract with proved dopaminergic activity for treatment of PMS accompanied by latent hyperprolactinemia is reasonable and save

Author Biography

А. Г. Резников, MD, professor, academician of the NAM S of Ukraine, corresponding member of NAS of Ukraine, chief of the Endocrinology of Reproduction and Adaptation Department

V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAM S Ukraine


  1. Vdovichenko, Y.P., Pakharenko, L.V. “The role of various hormones in the pathogenesis of premenstrual syndrome.” Pediatrics, Obstetrics and Gynecology, 4(2011): 216–218.
  2. Peresada, O.A. “Premenstrual syndrome: pathogenesis, clinical manifestations, treatment.” Medical News, 8(2010): 15–18.
  3. Reznikov, A.G., McCann, S.M., Rettori, V. “Study of pulse gonadotropin secretion of prolactin and response to luliberin in female rats after administer galanin in the III ventricle.” Endocrinology Problems, 4(1993): 40–42.
  4. Serov, V.N., Prylepskaia, V.N., Ovsyannikova, T.V. Gynecological endocrinology. M. MEDpress-inform (2004): 528 p.
  5. Smetnik, V.P., Tumilovich, V.G. Non-immediate gynecology: guidelines for physicians. M. MIA (1998): 592 p.
  6. Tatarchuk, T.F., Ventskovskaia, I.B. “The modern view on the treatment of premenstrual tension syndrome (PMS).” Health of Ukraine, 91(2004).
  7. Tatarchuk, T.F., Ventskovskaia, I.B., Shevchuk, T.V. “Premenstrual syndrome is an interdisciplinary problem.” Art of Treatment, 4(010) (2004): 36–43.
  8. Tatarchuk, T.F., Solskyi, Y.P. Endocrine gynecology. K. Zapovit (2003): 300 p.
  9. Tatarchuk, T.F., Kalugina, L.V. “New directions in the treatment of premenstrual tension syndrome.” Women’s Health, 3(2009): 47–49.
  10. Tikhomirov, A.L., Ledenkova, A.A. “Relief of mastodynia at hormonal treatment of patients with uterine myoma.” Reproductive Endocrinology, 5(19) (2014): 86–90.
  11. C ramer, O.M., Parker, C.R. Jr., Porter J.C. “Estrogen inhibition of dopamine release into hypophysial portal blood.” Endocrinology, 104(1979): 419–422.
  12. D ickerson, L.M., Mazyck, P.J., Hunter, M.H. “Premenstrual Syndrome.” Am Fam Physician, 67(2003): 1743–1752.
  13. Frank, R.T. “The hormonal causes of premenstrual tension.” Arch Neurol Psychiatry, 26(1931): 1052–1057.
  14. Halaska, M., Beles, P., Gorkow, C., Sieder, C. “Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study.” Breast, 8(1999): 175–181.
  15. M cCann, S.M., Reznikov, A.G., Aguila, M.C., et al. “Role of galanin in control of hypothalamic pituitary function.” Wenner-Gren Symposium (T.Hokfelt, T.Bartfai, eds.). Stockholm. The MacMillian Press Ltd (1991): 307–319.
  16. R aus, K. “Daten sprechen fur den Einsatz von Vitex agnus castus.” NaturaMed, 3(2008): 14–15.
  17. R ettori, V., Gutkovska, J., Reznikov, A.G. “Inhibition of galanin (GAL) release from hypothalamus and pituitary of female rats with dopamine (DA ).” 73rd Annual Endocrine Society Meeting Abstracts, Washington DC, June 19-22, 1991. Washington (1991).
  18. Van Die, M.D., Burger, H.G., Teede, H.J., Bone, K.M. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Med, 79(2013): 562–575.
  19. Wuttke, W., Christoffel, H.J.V., Spengler, B., Seidlova-Wuttke, D. “Vitex Agnus-Castus. Pharmacology and clinical indications.” Taking care of a woman, 7(55) (2014): 14–18.
  20. W uttke, W., Seidlova-Wuttke, D., Jarry, H., Artymuk, N. “Der Stellenwert des Monchspfeffers (Vitex agnus-castus).” Zeitschrift fur Phytotherapie, 31(2010): 294–298.
  21. W uttke, W., Splitt, G., Gorkow, C., et al. “Brustschmerzen mit einem Agnus castus-haltigen arneimittel. Ergebnisse einer randomisienter, placebokontrollierten doppelblindstudie.” Geb Fra, 57(1997): 569–574.



How to Cite

Резников, А. Г. (2015). Neuroendocrine system as therapeutic target of vitex agnus castus fruit extract for premenstrual syndrome. REPRODUCTIVE ENDOCRINOLOGY, (21), 19–23.



Clinical lecture